Jul. 7 at 9:23 PM
Ceribell flexes legal muscle against Natus over EEG patents. Aggressive IP protection aligns with their 88% gross margins and growth trajectory.
$CBLL betting big on defensible tech - but litigation costs could pressure cash reserves. High-risk chess move in medtech.
https://www.sec.gov/Archives/edgar/data/1861107/000095017025094303/cbll-20250707.htm